Menu Search
Equities

BioLine RX Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
YP2A:STU

BioLine RX Ltd

Actions
  • Price (EUR)4.04
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-86.26%
  • Beta1.2936
Data delayed at least 15 minutes, as of Jan 29 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

  • Revenue in USD (TTM)12.74m
  • Net income in USD-2.98m
  • Incorporated2003
  • Employees28.00
  • Location
    BioLine RX LtdModi'in Technology Park2 HaMa'ayan StreetMODIIN 7177871IsraelISR
  • Phone+972 86429100
  • Fax+972 86429101
  • Websitehttps://www.biolinerx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.